Surgicel Original

Phase 3Small molecule

Takeda

Surgicel Original is one of 41 small molecule programs targeting Hemorrhage. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemorrhageRecruiting

HemorrhagePhase 3

Recruiting

Competition

Competitive Landscape

137 competitors in Hemorrhage

#DrugCompanyPhaseTrials

Cytotec

Pfizer

Phase 3

3 2

Cyklokapron

AAmring

Phase 3

10 3

Activase

Roche

Phase 3

1 4

Tylenol

KKenvue Brands

Phase 3

1 5

Glypressin

MMallinckrodt

Phase 3

1 6

Indocin

LLife Extension Foundation Inc.

Phase 3

1 7

Virazole

CConrado Roberto Hoffmann Filho

Phase 3

1 8

Zocor

OOrganon and Co

Phase 3

1 9

Betadine

BBecton, Dickinson and Company

Phase 3

1 10

Statins

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Hemorrhage

NCT06664775

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

Completed· Takeda logo

Takeda·Phase 3·NCT01500135·150 enrolled

Hemorrhage1 trial

An Open Label, Prospective, Randomized, Parallel Groups, Multicenter Study to Compare the Efficacy and Safety of TachoSil® Versus Surgicel™ Original (Oxidized Regenerated Cellulose) as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery.

Recruiting·CCorza Medical GmbH·Phase 3·NCT06664775·116 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Surgicel Original. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Surgicel Original compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Surgicel Original. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

Surgicel Original

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Efficacy and Safety1 trial

Hemorrhage1 trial

References

Drug Info

Quick Facts

Related News